Biologics are among the most expensive pharmaceuticals but have begun to lose their
exclusivity rights over the past 15 years, offering the possibility for biosimilar competition …

The introduction of anti-tumor necrosis factor α (TNFα) biologics significantly innovated
inflammatory bowel disease (IBD) treatment and increased medical costs. The recent …

Objective To evaluate the impact of the entry of biosimilars on the pricing of eight biologic
products in 57 countries and regions. Methods We utilized an interrupted time series design …

Introduction: Biological medicines have been assuming an important role among the
therapeutic options for several diseases, however, due to their complex production process …

Introduction A period of exclusivity for the first generics, as part of the patent linkage system,
was established in South Korea to provide an economic incentive for early generic entry …

Abstract Background The Chinese biosimilar industry has demonstrated rapid growth in
recent years. Limited evidence is available about biosimilar uptake at the national level. This …

Importance Biosimilar drugs provide cost-effective yet clinically indistinguishable
replications of target drugs. During initial development, this class of biologic medicines was …

Background Knowledge, attitudes and substitution laws of biosimilars are not consistent
across countries. Biosimilar acceptance among patients and healthcare professionals may …

Paucity of intellectual property rights information in the US biologics system a decade after
passage of the Biosimilars Act | PLOS Medicine Skip to main content Advertisement PLOS …

Advancements in the identification of molecular drug targets and new therapeutic options for
different cancer types have paved the way for target-based therapies for cancer. In this vein …